Pharmaceutical Grade Magnesium Hydroxide Market, By Purity (<=99% and >99%), By End User (Pharmaceutical Companies, Contract Research Organizations, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

The global pharmaceutical grade magnesium hydroxide market is estimated to be valued at USD 785.3 Mn in 2026 and is expected to reach USD 1,115.8 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033. Pharmaceutical grade magnesium hydroxide popularly known as milk of magnesia, is an ultra-pure inorganic compound which conform the stringent standards specified by various pharmacopoeia such as United States Pharmacopeia (USP) and European Pharmacopoeia (EP). In addition, the product finds its extensive application as active pharmaceutical ingredient (API) and an excipient in a range of applications such as antacids, laxatives, and magnesium supplements and oral formulations as an affordable and safe ingredient owing to its ultra-pure nature, effective buffering properties and benign safety profile. The global pharmaceutical grade magnesium hydroxide market is projected to experience substantial growth owing to the surging incidences of various gastrointestinal disorders and increasing sales of pharmaceutical as well as nutraceuticals products. Growing investment in the pharmaceutical sector in various developing countries and innovation in the purification processes and development of high-quality pharmaceutical ingredients are also likely to influence the market growth over the forecasted period. Market Dynamics The global pharmaceutical grade magnesium hydroxide market is poised for significant growth driven by the rising prevalence of gastrointestinal disorders, coupled with the increasing demand for antacids, laxatives and magnesium supplements, and the overall growth of the pharmaceutical and nutraceutical industry. Additionally, increasing pharmaceutical manufacturing activities in developing countries and ever-increasing standards set by pharmacopeia of high purity pharmaceutical ingredients and excipients has further strengthened the demand for pharmaceutical grade magnesium hydroxide. However, a number of constraints are present in the market, such as stringent regulatory compliance requirements, fluctuating raw material availability, and energy-intensive production processes. Nevertheless, the development of advanced pharmaceutical formulations, increasing demand for pediatric and geriatric medicines, and the growing adoption of self-medication and over-the-counter (OTC) healthcare products will offer new opportunities for growth in the pharmaceutical grade magnesium hydroxide market. Key Features of the Study • This report provides in-depth analysis of the global pharmaceutical grade magnesium hydroxide market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global pharmaceutical grade magnesium hydroxide market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Huber Engineered Materials, Kyowa Chemical Industry Co., Ltd., Nedmag B.V., Konoshima Chemical Co., Ltd., ICL Performance Products LP, Martin Marietta Magnesia Specialties, LLC, Tateho Chemical Industries Co., Ltd., ICL Group Ltd., Nabaltec AG, and UBE Corporation • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global pharmaceutical grade magnesium hydroxide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmaceutical grade magnesium hydroxide market Market Segmentation • Purity Insights (Revenue, USD Mn, 2021 - 2033) o <=99% o >99% • End User Insights (Revenue, USD Mn, 2021 - 2033) o Pharmaceutical Companies o Contract Research Organizations o Others • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Huber Engineered Materials o Kyowa Chemical Industry Co., Ltd. o Nedmag B.V. o Konoshima Chemical Co., Ltd. o ICL Performance Products LP o Martin Marietta Magnesia Specialties, LLC o Tateho Chemical Industries Co., Ltd. o ICL Group Ltd. o Nabaltec AG o UBE Corporation